Bioadaptives, INC. (BDPT) — SEC Filings

Q: What are the key financial highlights for Bioadaptives, INC.?

Key financial highlights for Bioadaptives, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Bioadaptives, INC.?

Key executives at Bioadaptives, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Bioadaptives, INC. stock?

Risk factors for Bioadaptives, INC. (BDPT) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Bioadaptives, INC.?

Forward-looking statements and predictions from Bioadaptives, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Bioadaptives, INC.. Recent 10-Q filing on Nov 14, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Bioadaptives, INC. on SEC EDGAR

Overview

Bioadaptives, INC. (BDPT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: BIOADAPTIVES, INC. (BDPT) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $734,552, up from $527,373 in the prior year, representing a 39.3% increase. Revenue for the nine-month period decreased to $7,851 in 2025 from $12,669 in 2024, a 38% decline.

Sentiment Summary

Across 17 filings, the sentiment breakdown is: 2 bearish, 15 neutral. The dominant filing sentiment for Bioadaptives, INC. is neutral.

Filing Type Overview

Bioadaptives, INC. (BDPT) has filed 6 10-Q, 2 10-K, 8 8-K, 1 SC 13D with the SEC between Apr 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (17)

BioAdaptives' Losses Mount Amid Soaring Expenses, Cash Dwindles — 10-Q · Nov 14, 2025 Risk: high
BIOADAPTIVES, INC. (BDPT) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $734,552, up from $527,373 in the p
BioAdaptives Narrows Q2 Loss, Raises Capital Amid Going Concern Doubts — 10-Q · Aug 14, 2025 Risk: high
BioAdaptives, Inc. (BDPT) reported a net loss of $157,914 for the three months ended June 30, 2025, an improvement from a net loss of $183,017 in the same perio
BioAdaptives Q1 2025: $9M Revenue, $125M Assets — 10-Q · May 13, 2025 Risk: medium
BioAdaptives, Inc. filed its Q1 2025 10-Q report for the period ending March 31, 2025. The company reported revenue of $9,048,659. Key financial figures include
BioAdaptives, Inc. Files 2024 10-K — 10-K · Apr 15, 2025 Risk: medium
BioAdaptives, Inc. filed its 2024 10-K on April 15, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, formerl
BioAdaptives, Inc. Files 8-K Report — 8-K · Mar 18, 2025 Risk: low
BioAdaptives, Inc. filed an 8-K on March 18, 2025, reporting an event on March 13, 2025. The filing is a current report pursuant to Section 13 or 15(d) of the S
BioAdaptives Announces Board and Compensation Changes — 8-K · Feb 7, 2025 Risk: medium
BioAdaptives, Inc. announced on February 3, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure o
BioAdaptives, Inc. Files 8-K — 8-K · Dec 5, 2024 Risk: low
BioAdaptives, Inc. filed an 8-K on December 5, 2024, reporting an event on December 3, 2024. The filing is a Regulation FD Disclosure and includes Financial Sta
BioAdaptives Files 8-K: Regulation FD Disclosure — 8-K · Nov 27, 2024 Risk: low
BioAdaptives, Inc. filed an 8-K on November 27, 2024, reporting events as of November 26, 2024. The filing is primarily a Regulation FD Disclosure and includes
BioAdaptives, Inc. Files 8-K — 8-K · Nov 20, 2024 Risk: low
BioAdaptives, Inc. filed an 8-K on November 20, 2024, reporting events as of May 20, 2024. The filing primarily concerns Regulation FD disclosures, other events
BioAdaptives, Inc. Q3 2024 10-Q Filing — 10-Q · Nov 19, 2024 Risk: medium
BioAdaptives, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $1,250,000,000 and total liabilities of $895,76
BioAdaptives, Inc. Files 8-K — 8-K · Oct 30, 2024 Risk: low
BioAdaptives, Inc. filed an 8-K on October 30, 2024, reporting an event on October 28, 2024. The filing indicates a Regulation FD Disclosure, Other Events, and
Azuna Health LLC Files SC 13D for BioAdaptives Inc. — SC 13D · Oct 22, 2024 Risk: medium
Azuna Health LLC, through its filing on October 22, 2024, has reported a change in its beneficial ownership of BioAdaptives Inc. The filing indicates a shift in
BioAdaptives Reports Q2 2024 Results — 10-Q · Aug 19, 2024 Risk: medium
BioAdaptives, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $1.25 billion and total liabilities of $895.8 millio
BioAdaptives Appoints New Director, Officer Compensation Disclosed — 8-K · May 22, 2024 Risk: medium
BioAdaptives, Inc. announced on May 20, 2024, the departure of Director David L. Miller and the appointment of Dr. Robert L. Smith as a new director. The compan
BioAdaptives Q1 2024: Assets $1.15B, Liabilities $895M — 10-Q · May 17, 2024 Risk: medium
BioAdaptives, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported total assets of $1,154,770,641 and total liabilities of $895,760,22
BioAdaptives Changes Auditors — 8-K · May 14, 2024 Risk: medium
BioAdaptives, Inc. announced on May 13, 2024, a change in its certifying accountant. The company has dismissed its previous independent registered public accoun
BioAdaptives, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Apr 10, 2024 Risk: low
BIOADAPTIVES, INC. (BDPT) filed a Annual Report (10-K) with the SEC on April 10, 2024. BioAdaptives, Inc. reported total assets of $895,760,225 as of December 3

Risk Profile

Risk Assessment: Of BDPT's 17 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Bioadaptives, INC.'s most recent 10-Q filing (Nov 14, 2025):

Revenue: $7,851
Net Income: -$734,552
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $59,273
Operating Margin: N/A
Total Assets: $124,360
Total Debt: $1,589,570

Key Executives

Chief Executive Officer
Dr. Edwarde Jacobs
James Keener
David L. Miller
Dr. Robert L. Smith
Robert Ellis
January One Thousand Twenty One

Industry Context

The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on substantial external funding to advance their pipelines. Success is driven by innovation, clinical trial outcomes, and effective commercialization strategies.

Top Tags

financials (7) · 10-Q (4) · disclosure (4) · 8-K (3) · Going Concern (2) · Net Loss (2) · Biotech (2) · preferred-stock (2) · 10-K (2) · filing (2)

Key Numbers

Net Loss: $734,552 — Increased from $527,373 in 2024 for the nine months ended September 30, 2025
Revenue: $7,851 — Decreased from $12,669 in 2024 for the nine months ended September 30, 2025
General and administrative expenses: $592,246 — Increased from $76,685 in 2024 for the nine months ended September 30, 2025
Cash: $59,273 — Decreased from $137,470 at December 31, 2024
Accumulated Deficit: $9,897,858 — As of September 30, 2025, indicating significant historical losses
Common shares outstanding: 12,008,659 — As of October 17, 2025
Total Current Liabilities: $1,589,570 — As of September 30, 2025
Total Assets: $124,360 — As of September 30, 2025
Increase in Net Loss: 39.3% — For the nine months ended September 30, 2025, compared to 2024
Increase in Total Operating Expenses: 197% — For the nine months ended September 30, 2025, compared to 2024
Net Loss (Six Months): $355,050 — Decreased from $489,724 in prior year, but still significant.
Revenue (Six Months): $3,219 — Decreased from $12,669 in prior year, indicating weak sales.
Cash at End of Period: $210,582 — Increased from $137,470, primarily due to financing activities.
Proceeds from Series D Preferred Stock: $300,000 — Key source of cash for the period.
Net Cash Used in Operating Activities: $208,888 — For the six months ended June 30, 2025, indicating cash burn.

Frequently Asked Questions

What are the latest SEC filings for Bioadaptives, INC. (BDPT)?

Bioadaptives, INC. has 17 recent SEC filings from Apr 2024 to Nov 2025, including 8 8-K, 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of BDPT filings?

Across 17 filings, the sentiment breakdown is: 2 bearish, 15 neutral. The dominant sentiment is neutral.

Where can I find Bioadaptives, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Bioadaptives, INC. (BDPT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Bioadaptives, INC.?

Key financial highlights from Bioadaptives, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for BDPT?

The investment thesis for BDPT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Bioadaptives, INC.?

Key executives identified across Bioadaptives, INC.'s filings include Chief Executive Officer, Dr. Edwarde Jacobs, James Keener, David L. Miller, Dr. Robert L. Smith and 2 others.

What are the main risk factors for Bioadaptives, INC. stock?

Of BDPT's 17 assessed filings, 2 were flagged high-risk, 9 medium-risk, and 6 low-risk.

What are recent predictions and forward guidance from Bioadaptives, INC.?

Forward guidance and predictions for Bioadaptives, INC. are extracted from SEC filings as they are enriched.